Diabetes Mellitus and Risk of Prostate Cancer: a Meta-analysis
Overview
Authors
Affiliations
Aims/hypothesis: The association of diabetes mellitus with prostate cancer has been controversial. This study examines the strength of this association by conducting a detailed meta-analysis of the studies published in peer-reviewed literature on the subject.
Methods: A comprehensive search for articles published up to 2003 was performed, reviews of each study were conducted and data were abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) was calculated using the random- and the fixed-effects models. Subgroup and sensitivity analyses were also performed.
Results: We included 14 studies, published between 1971 and 2002, in the meta-analysis (five case-control studies, nine cohort studies). We found no evidence of publication bias ( p=0.89) or heterogeneity among the studies ( p=0.38). The association of diabetes with prostate cancer was statistically significant, both on the basis of a random-effects model (RR=0.91, 95% CI: 0.86 to 0.96), and on the basis of a fixed-effects model (RR=0.91, 95% CI: 0.88 to 0.94). When the analysis was stratified into subgroups according to study design, the association was inverse in both cohort and case-control studies, but only in the former was it statistically significant. The sensitivity analysis strengthened our confidence in the validity of this association.
Conclusions/interpretation: Our meta-analysis findings provide strong evidence that people with diabetes have a significant decrease in risk of developing prostate cancer. There is biological evidence to support this association.
Diabetes Mellitus and Prostate Cancer Risk-A Systematic Review and Meta-Analysis.
Drab A, Wdowiak K, Kanadys W, Zajaczkowski K, Koczkodaj P, Religioni U Cancers (Basel). 2024; 16(23).
PMID: 39682196 PMC: 11640538. DOI: 10.3390/cancers16234010.
Sharma N, Khatib M, Balaraman A, Roopashree R, Kaur M, Srivastava M Int Urol Nephrol. 2024; 57(4):1039-1049.
PMID: 39495435 DOI: 10.1007/s11255-024-04266-4.
A Mendelian randomization study between metabolic syndrome and its components with prostate cancer.
Xia L, Yu X, Wang L, Yang L, Bao E, Wang B Sci Rep. 2024; 14(1):14338.
PMID: 38906920 PMC: 11192917. DOI: 10.1038/s41598-024-65310-y.
Ye G, Yang Y, Luo K, Wang S, Xia Q Aging (Albany NY). 2024; 16(11):9584-9598.
PMID: 38836754 PMC: 11210264. DOI: 10.18632/aging.205886.
Metformin: A Dual-Role Player in Cancer Treatment and Prevention.
Galal M, Al-Rimawi M, Hajeer A, Dahman H, Alouch S, Aljada A Int J Mol Sci. 2024; 25(7).
PMID: 38612893 PMC: 11012626. DOI: 10.3390/ijms25074083.